Skip to main content
Rheumatoid Arthritis
Disease State Hub
Menu
Menu
Main navigation
Home
Education
Featured Topics
Acute Hepatic Porphyria
Alzheimer Disease
COVID-19
Depression Care 360
Diabetes Technology
Digital Health Solutions in Diabetes
HER2-Positive Early Breast Cancer
HIV Management
Neuromyelitis Optica Spectrum Disorder
Primary Hyperoxaluria
Ulcerative Colitis
Resources
Atlas of Lumps and Bumps
Case Presentations
Commentary
Disease State and Specialty Directory
FDA Alerts
Pearls
Podcasts
Polls
Q&A
Quizzes
Research Summaries
Slideshows
Videos
Multidisciplinary Roundtables
Featured Conferences
ACR Convergence
AIBD
American Heart Association Scientific Sessions
American Association of Neurological Surgeons Annual Meeting
American Society of Hematology Annual Meeting & Exposition
Consultant360's Practical Updates in Primary Care
Conference on Retroviruses and Opportunistic Infections
Infectious Diseases Society of America’s IDWeek
Society of Gynecologic Oncology Annual Meeting
International AIDS Conference
Society of Hematologic Oncology's Annual Meeting
Clinical Updates
Allergic Asthma
Alzheimer Disease
Cardiovascular Disease
Endometrial Cancer
Endometriosis
Eosinophilic Disorders
Exocrine Pancreatic Insufficiency
Generalized Pustular Psoriasis
Major Depressive Disorder
Nasal Polyps
Ovarian Cancer
Rheumatoid Arthritis
Schizophrenia
Ulcerative Colitis
Publication
About Consultant
Advertising With Consultant360
Author Guidelines
Call for Papers
Case Report Templates
Consultant Current Issue
Consultant Archive
Consultant Early View
FAQ
Get Permissions
Job Board
Get Permissions
Search
Contact
Login
Menu
Menu
Main navigation
Home
Education
Featured Topics
Acute Hepatic Porphyria
Alzheimer Disease
COVID-19
Depression Care 360
Diabetes Technology
Digital Health Solutions in Diabetes
HER2-Positive Early Breast Cancer
HIV Management
Neuromyelitis Optica Spectrum Disorder
Primary Hyperoxaluria
Ulcerative Colitis
Resources
Atlas of Lumps and Bumps
Case Presentations
Commentary
Disease State and Specialty Directory
FDA Alerts
Pearls
Podcasts
Polls
Q&A
Quizzes
Research Summaries
Slideshows
Videos
Multidisciplinary Roundtables
Featured Conferences
ACR Convergence
AIBD
American Heart Association Scientific Sessions
American Association of Neurological Surgeons Annual Meeting
American Society of Hematology Annual Meeting & Exposition
Consultant360's Practical Updates in Primary Care
Conference on Retroviruses and Opportunistic Infections
Infectious Diseases Society of America’s IDWeek
Society of Gynecologic Oncology Annual Meeting
International AIDS Conference
Society of Hematologic Oncology's Annual Meeting
Clinical Updates
Allergic Asthma
Alzheimer Disease
Cardiovascular Disease
Endometrial Cancer
Endometriosis
Eosinophilic Disorders
Exocrine Pancreatic Insufficiency
Generalized Pustular Psoriasis
Major Depressive Disorder
Nasal Polyps
Ovarian Cancer
Rheumatoid Arthritis
Schizophrenia
Ulcerative Colitis
Publication
About Consultant
Advertising With Consultant360
Author Guidelines
Call for Papers
Case Report Templates
Consultant Current Issue
Consultant Archive
Consultant Early View
FAQ
Get Permissions
Job Board
Get Permissions
Advertisement
Treatment
Pop Quiz: Treat-to-Target Recommendations for RA
Copied to clipboard
<section><h2></h2></section><section><h2><h2><p>True or False: According to the American College of Rheumatology’s <a href="https://www.rheumatology.org/Portals/0/Files/ACR%202015%20RA%20Guideline.pdf" target="_blank">guideline</a> on rheumatoid arthritis (RA) treatment, a treat-to-target strategy should be reserved only for patients with established RA and not implemented among patients with symptomatic early RA.</p></h2></h2></section><section><h2><p>Better luck next time</p></h2><p><p>According to the guideline authors:<br /></p><p>“Despite the low-quality evidence, the recommendation [for symptomatic early RA] is strong because the Voting Panel concluded that the improved outcomes experienced by patients with established RA using a targeted approach should be generalizable to those with early RA.”<br /></p><p>“The recommendation [for established RA] is strong because, based on moderate quality evidence, the panel concluded that the benefits far outweigh the risks for patients with established RA treated with a targeted approach compared to a nontargeted approach.”<br /></p><p>For more RA content, visit the <a href="https://www.consultant360.com/specialty/rheumatology/rheumatoid-arthritis" target="_blank">Resource Center</a>.</p></p></section><section><h3><p><strong>Nice job!</strong></p></h3><p><p>According to the guideline authors:</p><p>“Despite the low-quality evidence, the recommendation [for symptomatic early RA] is strong because the Voting Panel concluded that the improved outcomes experienced by patients with established RA using a targeted approach should be generalizable to those with early RA.”</p><p>“The recommendation [for established RA] is strong because, based on moderate quality evidence, the panel concluded that the benefits far outweigh the risks for patients with established RA treated with a targeted approach compared to a nontargeted approach.”</p><p>For more RA content, visit the <a href="https://www.consultant360.com/specialty/rheumatology/rheumatoid-arthritis" target="_blank">Resource Center</a>.</p></p></section>
advertisement
Advertisement
Advertisement
